SNY

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Sanofi - ADR

La vocation de Sanofi est d'accompagner celles et ceux confrontés à des difficultés de santé. Entreprise biopharmaceutique mondiale spécialisée dans la santé humaine qui prévient les maladies avec ses vaccins et propose des traitements innovants. Elle accompagne tant ceux qui sont atteints de maladies rares, que les millions de personnes souffrant d'une maladie chronique. Sanofi et ses plus de 100 000 collaborateurs dans 100 pays transforment l'innovation scientifique en solutions de santé partout dans le monde. Sanofi, Empowering Life, donner toute sa force à la vie.
CEO
Olivier Brandicourt
Employees
99412
Headquarters

54 Rue la Boetie
Paris, Ile De France 75008
Phone: 33153774000
www.sanofi.com

News

''Airbnb Has Foundational Cracks'', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft''s Nadella Criticizes Google''s Exclusive Content Deals: Today''s Top Stories
Oct 03, 2023 14:11pm

Benzinga Microsoft''s Nadella Criticizes Google''s Exclusive Content Deals Amid Antitrust Case In a significant development, Microsoft Corp''s (NASDAQ: MSFT ) CEO, Satya Nadella , has voiced concerns over the competitive landscape of content acquisition essential for training artificial intelligence (AI). Nadella''s remarks came during his testimony in a landmark antitrust trial in the U.S., where he highlighted the challenges posed by exclusive deals that tech giants, notably Alphabet Inc (NASDAQ: GOOGL ) (NASDAQ: GOOG ) Google, are securing with publishers. AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug AstraZeneca Plc (NASDAQ: AZN ) has agreed to pay $425 million to settle U.S. lawsuits related to heartburn and stomach acid treatments Nexium and Prilosec. The heartburn treatments have been under litigation, as some users said they caused kidney damage. Pharma Giants Sanofi, Johnson & Johnson Join Forces To Develop E.coli Vaccine Sanofi SA (NASDAQ: SNY ) struck a deal with Janssen Pharmaceuticals , a unit of Johnson & Johnson (NYSE: JNJ ), to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent).


Source:Benzinga
Sanofi teams up with J&J on E. coli vaccine with $175M upfront
Oct 03, 2023 13:05pm

Sanofi has added a late-stage can­di­date to its vac­cine fran­chise, pay­ing J&J’s Janssen $175 mil­lion up­front to part­ner on a shot that will pro­tect peo­ple from ex­train­testi­nal path­o­gen­ic E. coli. Janssen be­gan a Phase III tri­al of the …


Source:EIN News Pharmaceuticals
Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
Oct 03, 2023 12:32pm

… Janssen Pharmaceuticals . Under the terms of the deal, Sanofi will … executive vice president, vaccines at Sanofi , said: “E. coli is … than a month after Sanofi partnered with Ad Scientiam … with multiple sclerosis (MS). Sanofi also expanded its collaboration …


Source:EIN News Pharmaceuticals
Pharma Giants Sanofi, Johnson & Johnson Join Forces To Develop E.coli Vaccine
Oct 03, 2023 12:25pm

Sanofi SA (NASDAQ: SNY ) struck a deal with Janssen Pharmaceuticals , a unit of Johnson & Johnson (NYSE: JNJ ), to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) . The vaccine is currently in Phase 3 E.mbrace trial designed to evaluate the efficacy of the 9-valent extraintestinal pathogenic E. coli vaccine (ExPEC9V) compared to placebo in the prevention … Full story available on Benzinga.com


Source:Benzinga
Johnson & Johnson in pact with Sanofi for E. coli vaccine
Oct 03, 2023 12:10pm

Sanofi partners with Janssen to develop a vaccine for extraintestinal pathogenic E. coli, a leading cause of bloodstream infections in older adults. Read more here.


Source:Seeking Alpha
Sanofi In Agreement With Janssen To Develop E. Coli Vaccine
Oct 03, 2023 06:36am

NEW BRUNSWICK (dpa-AFX) - Sanofi (SNYNF) on Tuesday said it has entered into an agreement with Janssen Pharmaceuticals, Inc. , a Johnson & Johnson company, for the development of Janssen''s extrain…


Source:Finanz Nachrichten
Sanofi - Aventis Groupe: Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
Oct 03, 2023 05:34am

Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causin…


Source:Finanz Nachrichten
Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
Oct 03, 2023 05:30am

Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli Extraintestinal pathogenic E. coli (ExPEC)…


Source:GlobeNewswire
Sanofi (NASDAQ:SNY) Stake Lowered by Beacon Financial Group
Oct 02, 2023 14:16pm

Beacon Financial Group cut its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 6.0% in the 2nd quarter, Holdings Channel reports. The firm owned 15,183 shares of the company’s stock after selling 974 shares during the quarter. Beacon Financial Group’s holdings in Sanofi were worth $805,000 as of its most recent filing with […]


Source:The AM Reporter
Harrington Investments INC Has $313,000 Stock Position in Sanofi (NASDAQ:SNY)
Oct 01, 2023 16:16pm

Harrington Investments INC decreased its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 3.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,803 shares of the company’s stock after selling 190 shares during the quarter. Harrington Investments INC’s holdings in Sanofi […]


Source:The AM Reporter